Beta-blockers are an effective method to prevent mortality in patients with heart failure characterised by reduced ejection fraction (HFrEF) and sinus rhythm; this also applies to those individuals with moderate (eGFR 45-59 mL/min/1.73m2) or moderate-severe renal dysfunction (30-44 mL/min/1.73m2).
Renal insufficiency is a common feature in HF patients. The lack of evidence-based therapies in this population can be a real challenge. Kotecha and colleagues conducted an analysis using data from HFrEF patients (n=16,740) derived from 10 landmark, double-blind, placebo-controlled randomised trials to assess the role of beta-blockers in HF patients with renal impairment. Primary endpoint was all-cause mortality. Median age of the patients was 65 years; 23% were female and the median follow-up was 1.3 years. In general, it can be stated that renal dysfunction was independently associated with higher mortality. The cause of death was more often due to progressive ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Complete revascularisation superior to culprit-lesion-only PCI Next Article
Omega-3 fatty acid supplements may offer cardiovascular protection »
Table of Contents: ESC 2019
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.